Imagion Biosystems is pleased to announce a partnership with the ASX-listed therapeutic antibody development company Patrys Limited. The collaborative research program aims to combine Imagion Biosystems MagSense® technology with Patrys novel deoxymabs antibody to develop a highly effective imaging agent for hard-to-diagnose cancers, such as brain cancer.
Bob Proulx, Executive Chairman of Imagion Biosystems, said, “We are very interested in the tumor targeting capabilities of Patrys deoxymabs and believe there is potential for them to be paired with our MagSense® nanoparticles for many types of solid tumors. Initially, we are very keen to investigate the potential for brain tumor imaging since there is such a high unmet need for differentiating cancerous tumors in the brain, like glioblastoma, as well as metastatic disease that has spread to the brain from other primary tumors.”
Read the full announcement here: https://bit.ly/2Sn6Nsz
